Solid Tumors clinical trials
Showing 1,051–1,100 of 1,133 active trials. Describe your situation to see which ones look like a fit.
- Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing
- Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
- Photobiomodulation for Cancer-Related Cognitive Impairment
- Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
- my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
- Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE
- Community Health Worker Based Intervention to Improve Palliative Care
- Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- Exceptional Responders With Solid Tumor Cancer to Chemotherapy
- Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
- A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
- Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience
- Development and Application of Patient-Derived Models of Cancer
- Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
- Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness
- A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
- Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
- Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy
- Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
- Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
- Harvesting Cells for Experimental Cancer Treatments
- KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice
- A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
- Clinical Trial to Treat Stage IV Cancer Patients
- Social Needs App for Oncology Patients Phase II
- Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
- Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
- Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive Interventions
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
- Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
- A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
- A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- First in Human Study of AZD9592 in Solid Tumors
- A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Concurrent Azeliragon With Craniospinal Irradiation
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
- A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.